Date

Attendees

Committee MemberPresentAbsent
X
X
Warren KibbeX


Gregory TawaX
William Hendriks
X
Matthew Breen
X
Roel VerhaakX



Goals

Outstanding Action items

Agenda

Discussion ItemWhoNotes
New data submission request
Data submission approved by Senior Advisory Committee
  • "Immune Pathways and TP53 missense mutations are associated with longer survival in canine osteosarcoma" 
  • Data Submission Folder: OSA-Normal
  • Onboarding meeting set up with submitters
  • Study will be called OSA02
  • New program for Colorado State
PRECINCT Data Request Submission: Inhaled IL-15 Immunotherapy for Treatment of Lung Metastases

All

Review of other Modiano publications: Other Modiano Publication Considerations.xlsx
Study Updates
  • TCL01
    • Study identifier changed to TCL01 (Tumor Cell Line)
    • Testing completed
    • Pending release record available on production
    • Study files have been received
    • Files have been indexed by DCF
    • Study likely to be released this week
  • PRECINCT
    • Program now available on lower tier (dev environment)
    • Study record is in place
    • Working on Adverse Event node
    • Need follow-up call 
  • PANCAN01 (15 TB Re-analysis)
    • Data is already in a ICDC S3 bucket
    • Template-driven study onboarding initiated
    • One study will be onboarded at a time
    • Waiting on data submitters
  • Data submission guidelines have been updated and will be pushed to production soon

Minutes (Not Verbatim)



**Questions answered from email sent to submitters on 10//22**

  1. The ICDC is comprised of cases of spontaneous arising cancer in canines. Is there some implied linkage between thyroid tumors and IBD?
  2. How many of the 100 animals were controls?
  3. Is there any molecular data available for these subjects or tissues?
  4. The submission request form mentions 5 manuscripts being written based on the data, are any of these genomics or proteomics studies with molecular-level data?
  5. Is there any clinical metadata available for these subjects (breed, age, sex, disease)?

**Questions answered from email sent to submitters on 10/13/22**

  1. How many of the canine patient samples will ultimately have omics data associated with them?
  2. Are metadata available for the cancer-related samples?
  3. Are the organoids validated and are they available for other researchers?
  4. Is there a long-term plan to have genomic coverage for all individuals?
  5. Will these data be made accessible to the public in any other repository?

**Q&A Session**

  1. Will screening data be available in the future?
  2. Are there publications?
  3. Will the organoids be made available to other researchers?
  4. As a researcher interested in testing a particular compound...
  5. How do other labs reproduce research on the organoids?
    1. There is a paper coming out that gives exact specifications, collaborations are possible, but the organoids would stay at Iowa State. Open to colloabortions with industry and academia.


Action items